These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11352906)

  • 21. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
    Brodbeck WG; Mold C; Atkinson JP; Medof ME
    J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.
    Chen S; Caragine T; Cheung NK; Tomlinson S
    Cancer Res; 2000 Jun; 60(11):3013-8. PubMed ID: 10850450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.
    Bjørge L; Jensen TS; Matre R
    Cancer Immunol Immunother; 1996 Mar; 42(3):185-92. PubMed ID: 8640847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction.
    Mason JC; Lidington EA; Ahmad SR; Haskard DO
    Am J Physiol Cell Physiol; 2002 Mar; 282(3):C578-87. PubMed ID: 11832343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homologous restriction of complement-mediated cell lysis can be markedly enhanced by blocking decay-accelerating factor.
    Zhong RK; Kozii R; Ball ED
    Br J Haematol; 1995 Oct; 91(2):269-74. PubMed ID: 8547061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes.
    Ohta R; Imai M; Fukuoka Y; Miwa T; Okada N; Okada H
    Microbiol Immunol; 1999; 43(11):1045-56. PubMed ID: 10609614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.
    White J; Lukacik P; Esser D; Steward M; Giddings N; Bright JR; Fritchley SJ; Morgan BP; Lea SM; Smith GP; Smith RA
    Protein Sci; 2004 Sep; 13(9):2406-15. PubMed ID: 15322283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coxsackie B viruses that use human DAF as a receptor infect pig cells via pig CAR and do not use pig DAF.
    Spiller OB; Goodfellow IG; Evans DJ; Hinchliffe SJ; Morgan BP
    J Gen Virol; 2002 Jan; 83(Pt 1):45-52. PubMed ID: 11752699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin.
    Kinderlerer AR; Pombo Gregoire I; Hamdulay SS; Ali F; Steinberg R; Silva G; Ali N; Wang B; Haskard DO; Soares MP; Mason JC
    Blood; 2009 Feb; 113(7):1598-607. PubMed ID: 19036700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
    Coyne KE; Hall SE; Thompson S; Arce MA; Kinoshita T; Fujita T; Anstee DJ; Rosse W; Lublin DM
    J Immunol; 1992 Nov; 149(9):2906-13. PubMed ID: 1383332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular and functional analysis of mouse decay accelerating factor (CD55).
    Harris CL; Rushmere NK; Morgan BP
    Biochem J; 1999 Aug; 341 ( Pt 3)(Pt 3):821-9. PubMed ID: 10417349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.
    Ahmad SR; Lidington EA; Ohta R; Okada N; Robson MG; Davies KA; Leitges M; Harris CL; Haskard DO; Mason JC
    Immunology; 2003 Oct; 110(2):258-68. PubMed ID: 14511240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of the xenoantigenicity of neonatal porcine islet-like cell clusters (NPCC) and the efficiency of adenovirus-mediated DAF (CD55) expression.
    Omori T; Nishida T; Komoda H; Fumimoto Y; Ito T; Sawa Y; Gao C; Nakatsu S; Shirakura R; Miyagawa S
    Xenotransplantation; 2006 Sep; 13(5):455-64. PubMed ID: 16925670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
    Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
    Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative contributions of decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 in the protection of melanocytes from homologous complement.
    Venneker GT; Vodegel RM; Okada N; Westerhof W; Bos JD; Asghar SS
    Immunobiology; 1998 Feb; 198(4):476-84. PubMed ID: 9562871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of decay-accelerating factor expression and alpha1,3-galactosyltransferase knockout affords added protection from human complement-mediated injury.
    van Denderen BJ; Salvaris E; Romanella M; Aminian A; Katerelos M; Tange MJ; Pearse MJ; d'Apice AJ
    Transplantation; 1997 Sep; 64(6):882-8. PubMed ID: 9326415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
    Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
    Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M; Yefenof E; Klein G; Klein E
    Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).
    Qian YM; Haino M; Kelly K; Song WC
    Immunology; 1999 Oct; 98(2):303-11. PubMed ID: 10540231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.